World's Best Scientists 2026 revealed!
Torsten Pietsch

Torsten Pietsch

D-Index & Metrics

Medicine

D-Index
124
Citations
58482
World Ranking
3218
National Ranking
173

Torsten Pietsch publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Torsten Pietsch sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 692 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Torsten Pietsch D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Torsten Pietsch sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 124 D-Index — 84th percentile

84% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1996 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Torsten Pietsch is affiliated with the University of Bonn in Germany. Their research spans areas primarily within medicine and biochemistry, genetics, and molecular biology. Their work is concentrated in several subfields including genetics, molecular biology, neurology, pulmonary and respiratory medicine, and epidemiology.

The main topics of their research cover:

  • Glioma Diagnosis and Treatment
  • Neuroblastoma Research and Treatments
  • Brain Metastases and Treatment
  • Meningioma and schwannoma management
  • Chromatin Remodeling and Cancer
  • Hedgehog Signaling Pathway Studies
  • Radiomics and Machine Learning in Medical Imaging

Pietsch has contributed to numerous highly specialized publications. Some recently published papers include:

  • "cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading", 2020, Brain Pathology
  • "Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes", 2020, Cancer Discovery
  • "Multiomic neuropathology improves diagnostic accuracy in pediatric neuro-oncology", 2023, Nature Medicine
  • "Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort", 2020, Journal of Clinical Oncology
  • "Supratentorial ependymoma in childhood: more than just RELA or YAP", 2021, Acta Neuropathologica

The frequent publication venues for their work are:

  • Neuro-Oncology
  • Acta Neuropathologica
  • Neuro-Oncology Advances
  • Journal of Neuro-Oncology
  • Journal of Clinical Oncology

Collaborations play a significant role in their research activities. Frequent co-authors include:

  • Stefan Rutkowski
  • Brigitte Bison
  • Stefan M. Pfister
  • Martin Mynarek
  • Monika Warmuth-Metz

Pietsch was recognized as a Fellow of the American Association for the Advancement of Science (AAAS) in 1996.

Best Publications

  • DNA methylation-based classification of central nervous system tumours

    David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt

  • Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias.

    Walter Stummer;Hanns-Jürgen Reulen;Thomas Meinel;Uwe Pichlmeier

  • Negative Feedback Loop of Wnt Signaling through Upregulation of Conductin/Axin2 in Colorectal and Liver Tumors

    Barbara Lustig;Boris Jerchow;Martin Sachs;Sigrid Weiler

  • Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

    Roger Stupp;Roger Stupp;Monika E Hegi;Thierry Gorlia;Sara C Erridge

  • Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

    Marcel Kool;Andrey Korshunov;Marc Remke;Marc Remke;David T.W. Jones

  • Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups

    Kristian W. Pajtler;Kristian W. Pajtler;Hendrik Witt;Martin Sill;David T.W. Jones

  • Long-term survival with glioblastoma multiforme

    Dietmar Krex;Barbara Klink;Christian Hartmann;Andreas Von Deimling

  • Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas

    Christian Hartmann;Christian Hartmann;Bettina Hentschel;Wolfgang Wick;Wolfgang Wick;David Capper

  • New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs

    Dominik Sturm;Dominik Sturm;Brent A. Orr;Umut H. Toprak;Volker Hovestadt

  • NOA-04 Randomized Phase III Trial of Sequential Radiochemotherapy of Anaplastic Glioma With Procarbazine, Lomustine, and Vincristine or Temozolomide

    Wolfgang Wick;Christian Hartmann;Corinna Engel;Mandy Stoffels

  • Integrated Genomics Identifies Five Medulloblastoma Subtypes with Distinct Genetic Profiles, Pathway Signatures and Clinicopathological Features

    Marcel Kool;Jan Koster;Jens Bunt;Nancy E. Hasselt

  • Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone

    Stefan Rutkowski;Udo Bode;Frank Deinlein;Holger Ottensmeier

  • Treatment of brain tumors

    Arnold C. Paulino;Bin S. Teh;Michelle Sadeh;Lynn Ashby

  • Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

    Michael Weller;Jörg Felsberg;Christian Hartmann;Hilmar Berger

  • International Society of Neuropathology-Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

    David N. Louis;Arie Perry;Peter Burger;David W. Ellison

  • Enhancer hijacking activates GFI1 family oncogenes in medulloblastoma

    Paul A. Northcott;Catherine Lee;Catherine Lee;Thomas Zichner;Adrian M. Stütz

  • High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial

    Eckhard Thiel;Agnieszka Korfel;Peter Martus;Lothar Kanz

  • Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma

    Roger Stupp;Monika E. Hegi;Bart Neyns;Roland Goldbrunner

  • NeuN: a useful neuronal marker for diagnostic histopathology.:

    H K Wolf;R Buslei;R Schmidt-Kastner;P K Schmidt-Kastner

  • Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone

    Stefan Rutkowski;Udo Bode;Frank Deinlein

Frequent Co-Authors

Stefan Rutkowski
Stefan Rutkowski Universität Hamburg
Stefan M. Pfister
Stefan M. Pfister German Cancer Research Center
Andreas von Deimling
Andreas von Deimling Heidelberg University
Guido Reifenberger
Guido Reifenberger Heinrich Heine University Düsseldorf
Michael Weller
Michael Weller University of Zurich
Andrey Korshunov
Andrey Korshunov German Cancer Research Center
Marcel Kool
Marcel Kool German Cancer Research Center
David T. W. Jones
David T. W. Jones German Cancer Research Center
David Capper
David Capper Charité - University Medicine Berlin
Manfred Westphal
Manfred Westphal Universität Hamburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine opens the door to a broad range of online degree options and specialized pathways. For those seeking fast entry into the healthcare field, lpn programs can be completed in less time than traditional programs, allowing graduates to start working and gaining experience quickly.

Many medical professionals are turning to advanced online degrees to further their expertise. If mental health interests you, online msn pmhnp programs prepare nurses for in-demand roles in psychiatric care, offering flexible online study with clinical experience.

Not all medical careers require a clinical background. Administrative paths like a cheapest online healthcare administration degree provide cost-effective routes into the business side of healthcare, managing operations or leading teams.

For career advancement in leadership and policy, the cost of mha degree is a key factor to consider, with many affordable options available online. These degrees can fast-track your move into higher management roles.

Best Scientists Citing Torsten Pietsch

Trending Scientists

Recently Published Articles